Brief: C4 Therapeutics Announces Positive Data From Cft7455 Phase 1 Trial In Relapsed/Refractory Multiple Myeloma

C4 Therapeutics

12/12/2023 21:09

Dec 12 (Reuters) - C4 Therapeutics Inc  CCCC.O :
    * C4 THERAPEUTICS ANNOUNCES POSITIVE DATA FROM CFT7455 PHASE
1
TRIAL IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
    * C4 THERAPEUTICS INC - DATA SUPPORT 14 DAYS ON/14 DAYS OFF
AS
OPTIMAL DOSING SCHEDULE
    * C4 THERAPEUTICS INC - CFT7455 IS WELL TOLERATED WITH
PROMISING
SIGNS OF ANTI-MYELOMA ACTIVITY
    * C4 THERAPEUTICS INC - COMPLETED MONOTHERAPY DOSE
ESCALATION
DEMONSTRATES ANTI-MYELOMA ACTIVITY AND IMMUNOMODULATORY EFFECTS
    * C4 THERAPEUTICS INC - DOSE ESCALATION CONTINUES FOR
CFT7455 IN
COMBINATION WITH DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE
MYELOMA
    * C4 THERAPEUTICS INC - CONTINUES TO ENROLL PATIENTS IN
PHASE 1
DOSE ESCALATION TRIAL EXPLORING CFT7455 AS A MONOTHERAPY FOR NHL
PATIENTS

Source text for Eikon:  ID:nGNX9DB3d1 
Further company coverage:  CCCC.O 

 ((Reuters.Briefs@thomsonreuters.com;))